Can surgery boost control of spread prostate cancer?

NCT ID NCT07766486

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This study tests whether robot-assisted removal of the prostate, along with lymph node dissection, can help control cancer in men with oligometastatic hormone-sensitive prostate cancer—cancer that has spread to a few spots in the spine or pelvis. Participants have been on hormone therapy for at least six months and have low PSA levels. The trial will track survival, cancer progression, quality of life, and side effects over two years to see if adding surgery to ongoing hormone therapy is beneficial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Robot-assisted radical prostatectomy with extended pelvic lymph-node dissection
What this could lead to
If successful, this approach could offer a way to better control oligometastatic prostate cancer, potentially improving survival and delaying progression when combined with hormone therapy.
What could go wrong
This is a small pilot study, so results may not apply broadly. Surgery carries risks like urinary complications, and it's unclear if it will improve outcomes over hormone therapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Direzione di Chirurgia Urologica, INOC, viale della Ricerca 7, 10060 Candiolo, Turin 10060

    Candiolo, Torino (TO), 10060, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.